A Phase Ib/II, Open-label, Multi-centre Study of INC280 in Combination With PDR001 or PDR001 Single Agent in Advanced Hepatocellular Carcinoma
The purpose of this study of INC280 and PDR001 is to characterize the safety, tolerability,
pharmacokinetics (PK), pharmacodynamics (PD) and antitumour activity of PDR001 administered
i.v. as a single agent or in combination with INC280 administered orally in adult patients
with advanced hepatocellular carcinoma (HCC).
View this trial on ClinicalTrials.gov
Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.
These resources are provided in partnership with the
Canadian Cancer Society